Publication:
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.

dc.contributor.authorPérez-Latorre, Leire
dc.contributor.authorBerenguer, Juan
dc.contributor.authorMicán, Rafael
dc.contributor.authorMontero, Marta
dc.contributor.authorCifuentes, Carmen
dc.contributor.authorPuig, Teresa
dc.contributor.authorSanz, José
dc.contributor.authorFerrero, Oscar L
dc.contributor.authorDe La Fuente, Belén
dc.contributor.authorRodríguez, Carmen
dc.contributor.authorReus, Sergio
dc.contributor.authorHernández-Quero, José
dc.contributor.authorGaspar, Gabriel
dc.contributor.authorPérez-Martínez, Laura
dc.contributor.authorGarcía, Coral
dc.contributor.authorForce, Luis
dc.contributor.authorVeloso, Sergio
dc.contributor.authorDe Miguel, Marta
dc.contributor.authorJarrín, Inmaculada
dc.contributor.authorGonzález-García, Juan
dc.contributor.authorGeSIDA 8514 Study Group
dc.date.accessioned2023-02-09T11:41:02Z
dc.date.available2023-02-09T11:41:02Z
dc.date.issued2021
dc.description.abstractBackgroundRecent and reliable estimates on the prevalence of coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) in Europe are lacking.AimLeveraged on a study designed to assess HIV/HCV coinfection prevalence, we assessed the prevalence of HIV/HBV coinfection in Spain in 2018 and compared the results with five similar studies performed since 2002.MethodsThis cross-sectional prevalence study was carried out in 43 centres, and patients were selected using simple random sampling. The reference population comprised 40,322 patients and the sample size were 1,690 patients.ResultsThe prevalence of HIV/HBV coinfection in Spain at the end of 2018 was 3.2%. The prevalence in 2002, 2009, 2015, 2016 and 2017 was 4.9%, 3.4%, 3%, 3.9% and 3%, respectively. Among the HIV/HBV-coinfected patients identified in 2018, 16.7% had cirrhosis according to transient elastography and 26.3% tested positive for antibodies against hepatitis D virus. All HIV/HBV-coinfected patients were receiving drugs with activity against HBV, and 97% of those tested for HBV DNA had an HBV DNA load 
dc.identifier.doi10.2807/1560-7917.ES.2021.26.25.2000236
dc.identifier.essn1560-7917
dc.identifier.pmcPMC8229377
dc.identifier.pmid34169818
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229377/pdf
dc.identifier.unpaywallURLhttps://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/26/25/eurosurv-26-25-4.pdf?itemId=%2Fcontent%2F10.2807%2F1560-7917.ES.2021.26.25.2000236&mimeType=pdf&containerItemId=content/eurosurveillance
dc.identifier.urihttp://hdl.handle.net/10668/18041
dc.issue.number25
dc.journal.titleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
dc.journal.titleabbreviationEuro Surveill
dc.language.isoen
dc.organizationHospital Universitario San Cecilio
dc.organizationHospital Universitario Virgen de las Nieves
dc.organizationHospital Universitario San Cecilio
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHBV therapy
dc.subjectHIV/HBV coinfection
dc.subjecthepatitis delta virus
dc.subject.meshCoinfection
dc.subject.meshCross-Sectional Studies
dc.subject.meshEurope
dc.subject.meshHIV Infections
dc.subject.meshHepatitis B
dc.subject.meshHepatitis B virus
dc.subject.meshHumans
dc.subject.meshPrevalence
dc.subject.meshSpain
dc.titleHIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number26
dspace.entity.typePublication

Files